Bernstein Reaffirms Price Target on Eli Lilly (LLY) After Breakthrough Gains

Eli Lilly & Company (NYSE:LLY) ranks among the Best Low Volatility Investments in December 2025. Eli Lilly & Company (NYSE:LLY) reached another milestone on November 21, becoming the first drugmaker to join the exclusive $1 trillion club populated by tech behemoths and cementing its position as a weight-loss powerhouse.

The company’s stock has rallied more than 35% this year, owing primarily to the staggering rise of the global weight-loss market.

Moreover, on November 24, Bernstein SocGen Group reiterated its Outperform rating on Eli Lilly & Company (NYSE:LLY) , with a $1,300 price target. The firm maintained a favorable view on the drug maker as Eli Lilly & Company (NYSE:LLY) continues to investigate potential in the Alzheimer’s disease field using incretin-based medicines.

According to Bernstein SocGen, Eli Lilly & Company (NYSE:LLY) would probably devise an alternate clinical trial method than the current trials, possibly addressing earlier-stage Alzheimer’s patients and using a drug like Brenipatide.

Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.